首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >The Usefulness of Xuefu Zhuyu Tang for Patients with Angina Pectoris: A Meta-Analysis and Systematic Review
【2h】

The Usefulness of Xuefu Zhuyu Tang for Patients with Angina Pectoris: A Meta-Analysis and Systematic Review

机译:血府逐瘀汤对心绞痛患者的有用性:荟萃分析和系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. To evaluate the efficacy of Xuefu Zhuyu Tang (XFZYT) for treating angina pectoris (AP). Methods. Six databases were searched (up to December, 2013). Eligible randomized controlled trials (RCTs) evaluating the efficiency of XFZYT plus traditional antianginal medications (TAMs) compared with TAMs alone in patients with AP were included. The outcomes were relief of anginal symptoms (RAS) and improvement of electrocardiogram (ECG) and blood high-density lipoprotein cholesterol (HDL-C) level. Result. Finally 14 RCTs were included. There were evidences that XFZYT combined with TAMs was more effective in improving RAS (RR = 1.29; 95% CI = [1.20, 1.38]), ECG (RR = 1.37; 95% CI = [1.22, 1.54]), and blood HDL-C level (MD = 0.29 mmol/L; 95% CI = [0.23, 0.35]) compared with TAMs alone. Our meta-analysis also showed the pooled number needed to treat (NNT) of the group with stable angina pectoris (SAP) was smaller in improving RAS (4.2 versus 5.7) and ECG (3.1 versus 5.5) compared with the group with both SAP and unstable angina pectoris (UAP). Conclusion. Combination therapy with XFZYT and TAMs is more effective in treating AP compared with TAMs alone. And XFZYT may be a more suitable choice for the treatment of SAP. However, the findings should be interpreted with caution due to the mediocre methodological quality of the included RCTs.
机译:目的。评估血府逐瘀汤(XFZYT)治疗心绞痛(AP)的疗效。方法。搜索了六个数据库(到2013年12月)。纳入了评估XFZYT加上传统抗心绞痛药物(TAM)相对于AP患者的TAM疗效的合格随机对照试验(RCT)。结果是缓解了心绞痛症状(RAS),改善了心电图(ECG)和血液高密度脂蛋白胆固醇(HDL-C)水平。结果。最终包括14个RCT。有证据表明,XFZYT与TAM联合使用对改善RAS(RR = 1.29; 95%CI = [1.20,1.38]),ECG(RR = 1.37; 95%CI = [1.22,1.54])和血液HDL更有效。与单独的TAMs相比,-C水平(MD = 0.29 mmol / L; 95%CI = [0.23,0.35])。我们的荟萃分析还显示,与同时使用SAP和SAP的组相比,稳定型心绞痛(SAP)组所需的合并治疗(NNT)数在改善RAS(4.2 vs. 5.7)和ECG(3.1 vs 5.5)方面较小。不稳定型心绞痛(UAP)。结论。与单独使用TAM相比,XFZYT和TAM联合治疗对AP的治疗更为有效。 XFZYT可能是治疗SAP更合适的选择。但是,由于所包括的随机对照试验的方法学质量中等,因此应谨慎解释研究结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号